Tan Li
Gründer bei SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
Vermögen: 584 Mio $ am 30.04.2024
Aktive Positionen von Tan Li
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | Direktor/Vorstandsmitglied | 21.04.1998 | - |
| Gründer | 21.04.1998 | - | |
| Corporate Officer/Principal | 21.04.1998 | - | |
| Urumqi Jintiantu Equity Investment Partnership LP | Corporate Officer/Principal | 09.08.2013 | - |
| Direktor/Vorstandsmitglied | 09.08.2013 | - | |
| Shenzhen Techdow Pharmaceutical Co., Ltd. | Direktor/Vorstandsmitglied | - | - |
Shenzhen Duopule Industrial Development Co., Ltd.
 Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | Direktor/Vorstandsmitglied | 13.01.2014 | - |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Direktor/Vorstandsmitglied | - | - |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Direktor/Vorstandsmitglied | 20.01.2017 | - |
Karriereverlauf von Tan Li
Ausbildung von Tan Li
| Sichuan University | Undergraduate Degree |
Statistik
International
| China | 6 |
| Vereinigtes Königreich | 3 |
Operativ
| Director/Board Member | 6 |
| Corporate Officer/Principal | 2 |
| Founder | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
| Distribution Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
| Urumqi Jintiantu Equity Investment Partnership LP | |
| Shenzhen Techdow Pharmaceutical Co., Ltd. | |
Shenzhen Duopule Industrial Development Co., Ltd.
Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | Distribution Services |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Health Technology |
